InMode (NASDAQ:INMD) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

InMode (NASDAQ:INMD) announced its earnings results on Tuesday. The healthcare company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04, FiscalAI reports. InMode had a net margin of 41.04% and a return on equity of 14.50%. The business had revenue of $103.85 million for the quarter, compared to the consensus estimate of $104.64 million. During the same period last year, the firm posted $0.42 earnings per share. InMode’s quarterly revenue was up 6.1% on a year-over-year basis.

Here are the key takeaways from InMode’s conference call:

• InMode expects 2026 to be a stabilization year, guiding 2026 revenue to $365M–$375M (broadly in line with 2025’s $370.5M) after a Q4 that showed slight improvement and a modest increase in consumables and services, which management views as early signs of patient activity stabilizing.
• International momentum drove a record Q4 in Europe: sales outside the U.S. were $48.5M (47% of Q4 revenue), up 38% YoY, and full-year international sales rose 15% to $171.8M, boosting geographic diversification.
• Product strategy emphasizes innovation and breadth — launched a CO2 platform in 2025 and plans to introduce a Korean-made Pico laser and a Morpheus+Erbium YAG combo in 2026 as part of a goal to release two new platforms per year to expand TAM and offer combined-treatment solutions.
• Management expects margin pressure in 2026 (NANGAP gross margin guided to 75%–77% vs. ~79% in 2025) and reported lower non‑GAAP operating margins and EPS YoY, attributing declines to lower‑margin imported laser products, U.S. tariffs on imports, and higher sales & marketing investments.
• Capital allocation and strategic review: InMode had $555.3M in cash/marketable securities, returned $127.4M to shareholders in 2025 (and ~ $508M via buybacks over prior years), and the board has engaged Bank of America to evaluate strategic alternatives while management’s involvement is limited.

InMode Stock Performance

NASDAQ:INMD opened at $14.62 on Wednesday. InMode has a fifty-two week low of $13.14 and a fifty-two week high of $19.78. The firm has a market cap of $924.12 million, a PE ratio of 6.77 and a beta of 2.19. The business has a 50 day moving average price of $14.67 and a 200-day moving average price of $14.69.

Trending Headlines about InMode

Here are the key news stories impacting InMode this week:

• Positive Sentiment: Q4 EPS beat and strong profitability — InMode reported $0.46 GAAP EPS versus the $0.42 consensus and delivered a high net margin (~41%), signaling operating leverage and healthy unit economics. MarketBeat Earnings Summary
• Neutral Sentiment: Top-line was slightly below expectations — Q4 revenue came in at $103.85M vs. an analyst estimate of $104.64M, though revenue was up ~6.1% year-over-year and full-year 2025 revenue totaled $370.5M. Slide deck and press release available for detail. PR Newswire Release
• Neutral Sentiment: Full earnings materials and transcripts posted — Investors can review the call transcript and slide deck for color on procedure demand and channel trends. Useful for modeling near-term service/device placements. Yahoo Earnings Highlights Seeking Alpha Transcript
• Neutral Sentiment: Short-interest data appears unreliable — a recent report shows “0” shares and no days-to-cover, which is likely a reporting artifact and not actionable. Treat short-interest signals with caution until corrected. (internal data entry)
• Negative Sentiment: Cautious 2026 outlook weighed on the stock — commentary on the Q4 call and company guidance was viewed as conservative by investors, and that caution appears to have offset the EPS beat and triggered the pullback in the share price. MSN: Stock Slips After Cautious Outlook

Analysts Set New Price Targets

Several brokerages recently issued reports on INMD. Weiss Ratings reiterated a “sell (d+)” rating on shares of InMode in a research report on Thursday, January 22nd. BTIG Research reissued a “neutral” rating on shares of InMode in a report on Monday, January 26th. UBS Group cut their target price on InMode from $16.25 to $16.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Canaccord Genuity Group set a $15.00 price target on shares of InMode and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Finally, Wall Street Zen lowered shares of InMode from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $16.60.

Institutional Investors Weigh In On InMode

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in shares of InMode by 5.7% during the first quarter. Royal Bank of Canada now owns 242,398 shares of the healthcare company’s stock worth $4,299,000 after purchasing an additional 13,032 shares during the period. AQR Capital Management LLC bought a new position in InMode during the 1st quarter valued at approximately $317,000. Goldman Sachs Group Inc. lifted its holdings in InMode by 234.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company’s stock worth $19,935,000 after buying an additional 788,157 shares during the period. American Century Companies Inc. grew its position in shares of InMode by 132.9% in the 2nd quarter. American Century Companies Inc. now owns 44,240 shares of the healthcare company’s stock worth $639,000 after buying an additional 25,246 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of InMode by 270.7% during the second quarter. Marshall Wace LLP now owns 555,573 shares of the healthcare company’s stock valued at $8,022,000 after buying an additional 405,707 shares during the period. Institutional investors own 68.04% of the company’s stock.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.